Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots SEC Filings
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Trends Where price, fundamentals and sentiment are pointing. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

INTS Intensity Therapeutics, Inc.

NASDAQ

$4.10

Intensity Therapeutics, Inc. (INTS) Earnings News

Earnings press releases and Earnings Whispers previews for Intensity Therapeutics, Inc. (INTS), newest first.

Tuesday August 11, 2026 7:30 AM ET

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tuesday August 4, 2026 8:00 AM ET

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Wednesday July 15, 2026 7:45 AM ET

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Wednesday July 1, 2026 8:00 AM ET

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Thursday May 14, 2026 8:00 AM ET

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thursday May 7, 2026 4:06 PM ET

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wednesday April 15, 2026 9:15 AM ET

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Friday March 27, 2026 4:12 PM ET

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Tuesday March 24, 2026 8:00 AM ET

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

Thursday March 12, 2026 7:30 AM ET

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study